Leishmanial infections are worldwide in distribution, occurring in Africa, North and South America, Southern Europe, and Asia. The clinical manifestations of leishmaniasis are extremely varied and include visceral, cutaneous, diffuse cutaneous, and mucosal disease. There are an estimated 15-20 million cases of leishmaniasis worldwide and there are neither leishmania vaccines nor standardized tests for diagnosis. The existing treatment is expensive and often requires hospitalization. Notwithstanding, the leishmaniases are excellent candidates for the development of vaccines, antigen-based therapeutics, cytokine therapy, and effective diagnostics. The goal of this project is to develop leishmania recombinant antigens for vaccine development which would have worldwide application and be affordable in the developing world. Over the past years we have cloned several leishmania antigens. Some of them have been more extensively studied because they primarily stimulate the T helper phenotype responsible for protection in leishmaniasis. Two such antigens deserve primary attention. One of them, a L. braziliensis protein (LeIF) which we recently described, stimulates peripheral blood mononuclear cells (PBMC) from leishmania infected patients to proliferate, to produce a Th1 type of cytokine profile and to down regulate the IL-10 mRNA from both resting and activated cells. LeIF also stimulates the production of both IL-12 p40 subunit and IL-12 p70 in cultured PBMC from patients and uninfected individuals. More recently we observed that LeIF has exceptional adjuvant properties with a variety of antigens. The second antigen was discovered by cloning a Leishmania donovani gene based on the sequence of a peptide isolated from MHC class II molecules of infected mouse macrophages. This antigen (Idp23) is a parasite cell surface-associated molecule and also stimulates Th1 type of response.
The specific aims are as follows: 1) To define both the adjuvant moiety and the antigenic epitope mapping of LeIF; 2) To characterize the biological mechanisms of the adjuvant property of LeIF; 3) To clone and characterize novel leishmania vaccine candidate antigens; and 4) To use selected recombinant leishmania antigens in experimental vaccination protocols in mice, hamsters and dogs. The results obtained from these experiments will have direct impact on the protocols of vaccine development for humans and potentially for the diagnosis of leishmaniasis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI025038-12
Application #
2671899
Study Section
Tropical Medicine and Parasitology Study Section (TMP)
Project Start
1993-11-01
Project End
2001-08-31
Budget Start
1998-09-01
Budget End
1999-08-31
Support Year
12
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Infectious Disease Research Institute
Department
Type
DUNS #
City
Seattle
State
WA
Country
United States
Zip Code
98102
Reed, Steven G; Carter, Darrick; Casper, Corey et al. (2018) Correlates of GLA family adjuvants' activities. Semin Immunol 39:22-29
Duthie, Malcolm S; Van Hoeven, Neal; MacMillen, Zachary et al. (2018) Heterologous Immunization With Defined RNA and Subunit Vaccines Enhances T Cell Responses That Protect Against Leishmania donovani. Front Immunol 9:2420
Duthie, Malcolm S; Lison, Aurore; Courtenay, Orin (2018) Advances toward Diagnostic Tools for Managing Zoonotic Visceral Leishmaniasis. Trends Parasitol 34:881-890
Duthie, Malcolm S; Reed, Steven G (2017) Not All Antigens Are Created Equally: Progress, Challenges, and Lessons Associated with Developing a Vaccine for Leishmaniasis. Clin Vaccine Immunol 24:
Sato, Camila Massae; Sanchez, Maria Carmen Arroyo; Celeste, Beatriz Julieta et al. (2017) Use of Recombinant Antigens for Sensitive Serodiagnosis of American Tegumentary Leishmaniasis Caused by Different Leishmania Species. J Clin Microbiol 55:495-503
Duthie, Malcolm S; Favila, Michelle; Hofmeyer, Kimberley A et al. (2016) Strategic evaluation of vaccine candidate antigens for the prevention of Visceral Leishmaniasis. Vaccine 34:2779-86
Hofmeyer, Kimberly A; Duthie, Malcolm S; Laurance, John D et al. (2016) Optimizing Immunization Strategies for the Induction of Antigen-Specific CD4 and CD8 T Cell Responses for Protection against Intracellular Parasites. Clin Vaccine Immunol 23:785-94
Schaut, Robert G; Grinnage-Pulley, Tara L; Esch, Kevin J et al. (2016) Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant. Vaccine 34:5225-5234
Carter, Darrick; Fox, Christopher B; Day, Tracey A et al. (2016) A structure-function approach to optimizing TLR4 ligands for human vaccines. Clin Transl Immunology 5:e108
Ghosh, Prakash; Bhaskar, Khondaker R H; Hossain, Faria et al. (2016) Evaluation of diagnostic performance of rK28 ELISA using urine for diagnosis of visceral leishmaniasis. Parasit Vectors 9:383

Showing the most recent 10 out of 80 publications